• Adlai Nortye received Australian HREC clearance for a Phase I trial of AN4035, a CEACAM5-targeting pan-RAS(ON) inhibitor antibody-drug conjugate.
• The company also filed a Clinical Trial Notification with Australia’s TGA to start the study.
• First patient dosing is expected in 2H 2026; IND filings with the U.S. FDA and China’s NMPA are in progress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adlai Nortye Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030700PRIMZONEFULLFEED9802234) on August 03, 2026, and is solely responsible for the information contained therein.